This article is more than 5 years old. Information may no longer be current.
Methyl aminolevulinate PDT effective in some eyelid basal cell carcinoma cases
Ophthal Plast Reconstr Surg. 2009;25(2):115-118.
Click Here to Manage Email Alerts
More than 80% of patients with eyelid basal cell carcinoma had complete clinical recovery at 5 years after treatment with methyl aminolevulinate photodynamic therapy, a study found.
"The absence of complications, good tolerance and a notable success rate make this nonsurgical procedure promising for the treatment of basal cell carcinoma of the eyelid in selected patients," researchers said.
In the retrospective study, 16 consecutive patients who had eyelid basal cell carcinoma received PDT using methyl aminolevulinate acid. Patients in the study had tumors at least 3 mm from the tarsus, were not indicated for surgery and had experienced recurrences undefined to location. Follow-up was up to 5 years.
After topical application of methyl aminolevulinate cream and occlusion for 4 hours, patients were treated with an 80-J cm2 light-emitting diode light source (632 nm), for a mean total of 3.1 sessions per patient.
At 5 years, 13 patients (82%) had "complete clinical recovery," the study said. Two patients did not respond to treatment, and one had a recurrence at 3 years.